US2020093792A1PendingUtilityA1
Use of amisulpride as an anti-emetic
Est. expiryMar 11, 2030(~3.7 yrs left)· nominal 20-yr term from priority
A61K 45/06A61K 31/573A61K 31/40A61K 9/0019A61K 31/282A61K 9/0031A61P 43/00A61K 31/4178A61K 47/12A61K 9/0014A61K 9/0053A61K 31/485A61P 1/00A61P 25/04A61P 1/08A61P 35/00A61K 33/24A61K 33/243
80
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Amisulpride is used in the therapy of nausea, vomiting or retches. The therapy may utilize a novel injectable formulation, in unit dosage form, comprising less than 50 mg amisulpride.
Claims
exact text as granted — not AI-modified1 . A pharmaceutical composition comprising amisulpride in an amount of less than 50 mg per dose, and a pharmaceutically acceptable carrier.
2 . A method for the prevention and/or treatment of post-operative nausea and vomiting, comprising administering amisulpride at a dose of less than 50 mg to a subject in need thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.